Pharmaceutical industry – Page 46
-
Business
Contamination troubles strike GSK
GlaxoSmithKline is warned over contamination at an Ireland plant, and has recalled Alli from US retailers over tampering concerns.
-
Business
Lilly wins cancer drug patent dispute
Alimta patent will last until 2022 after US court rules in Lilly’s favour
-
Business
Pharma giants plan new public–private collaborations
AstraZeneca and GSK will partner with UK academics to work on early drug discovery
-
Business
Baxter aims to divide and conquer
Firm will split off its biopharmaceuticals business from medical products
-
OpinionKnown unknowns
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe
-
Business
AstraZeneca boosts open innovation efforts
Web portal will make collaborative drug discovery easier
-
Business
$1.2bn J&J deceptive marketing fine overturned
Supreme court reverses decision to fine firm over Risperdal promotion
-
Business
US focuses pharma supply chain scrutiny
Import pre-authorisation for trusted firms frees up resources to tackle purity problems
-
Business
UK to fast-track access to critical medicines
Patients could receive medicines before formal approval in exchange for monitoring data
-
Business
Bristol-Myers Squibb to close Irish plant
130 jobs to go at manufacturing site in Cruiserath
-
BusinessMegamerger brings Actavis into R&D race
$25bn Forest Labs takeover will see generics giant take on patented products
-
BusinessRefined gels for cultured cells
Company profile: Biogelx makes self-assembled peptide hydrogels with tuneable properties
-
BusinessGenerics give injectables a shot
A rash of recent acquisitions sees generics companies eager to enter speciality manufacturing market
-
BusinessJ&J puts trial data in independent hands
Yale University’s YODA seeks to help pharma avoid the dark side by acting as gatekeeper for patient records
-
Business
Merck & Co doubles up on Ablynx research deal
Cancer nanobody R&D partnership could be worth €1.7 billion
-
FeatureThe hunt for innovation
Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom
-
OpinionBeelzebub Pharma Ltd
Derek Lowe thinks the Devil’s R&D management schemes might be scarily familiar
-
Business
AstraZeneca ends R&D in India
Bangalore site will close with loss of 168 jobs. Some projects will transfer to UK
-
Business
Jazz spending spree has ups and downs
Aerial sells Jazz rights to sleeping sickness drug but Gentium shareholders put brakes on earlier deal